Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$3.89B+4.10%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kirk L. Perry
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Employees
- 21,890
- Beta
- 0.45
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 2.23
Financials
Revenue
$3.89B+4.1%Net Income
$430.00M+4.6%EBITDA
$856.00M+23.5%Free Cash Flow
$620.00M-30.0%EPS (diluted)
$0.22+0.0%Shares Outstanding (diluted)
1.93B+2.0%Operating Expenses
$1.57BCash & Debt
$1.04BReturn of Capital
$403.00MRevenue by Segment (annual)
$15.12BDividend per Share
$0.21Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $15.12B | $1.47B | $0.77 |
| 2024 | $15.46B | $1.03B | $0.54 |
| 2023 | $15.44B | $1.66B | $0.90 |
| 2022 | $14.95B | $2.06B | $1.20 |
| 2021 | $15.05B | $2.08B | $1.21 |
| 2020 | $14.47B | $-879.00M | $-0.47 |
| 2019 | $14.32B | $1.44B | $0.76 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from KVUE's reported EPS growth of 0.2% a year over 6 years.
- EPS in 5 years
- $0.77
- Implied price
- $17.04
- Return from $19.31
- -2.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $8.47 — -56.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 19 | 22 | 25 | 28 |
|---|---|---|---|---|---|
| -9.8% | -17.6% | -14.7% | -12.2% | -9.9% | -7.9% |
| -4.8% | -13.1% | -10.0% | -7.3% | -4.9% | -2.8% |
| 0.2% | -8.5% | -5.3% | -2.5% | 0.1% | 2.3% |
| 5.2% | -3.9% | -0.6% | 2.4% | 5.0% | 7.5% |
| 10.2% | 0.6% | 4.2% | 7.3% | 10.0% | 12.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
75+7.14%Social Signal Score
Mentions (50)
- Newsfool.com·2d ago·Positive
Is Kimberly-Clark Stock a Buy Now That the Kenvue Acquisition Is Finalized? The maker of personal care products finalized its acquisition of Kenvue on Nov. 2. It expects cost savings and revenue gains to total $2.1 billion over the next several years.
View source ↗ - Newszacks.com·19d ago·Positive
Can Kimberly-Clark's Kenvue Acquisition Unlock Long-Term Growth? KMB's Kenvue acquisition expands its global health and wellness footprint, strengthening its brand portfolio and creating new avenues for long-term growth.
View source ↗ - Newsprnewswire.com·19d ago·Negative
Kimberly-Clark Corporation Announces Expiration and Final Results of Exchange Offers for Kenvue Notes DALLAS, Nov. 3, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the final results of the offers to exchange (each an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes (the "Kenvue Notes") issued by Kenvue LLC (as successor in interest to Kenvue Inc.) ("Kenvue") for up to $7,000,000,000 aggregate principal amo…
View source ↗ - Newsfool.com·19d ago·Positive
Kimberly-Clark Acquires Kenvue. Here's What Investors Need to Know Ahead of Its Nov. 5 Earnings Report. That's expensive, but the tie-up is complementary in several ways. The buyer is also likely to find a way of keeping its Dividend King status alive.
View source ↗ - News (Finnhub)CNBC·20d ago·Neutral
Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next Kimberly-Clark has a plan improve growth and earnings following its acquisition of Kenvue
View source ↗ - News (RSS)zerohedge·20d ago·Neutral
…an enterprise value $115 billion in a race to capitalize on the artificial intelligence boom. Lumentum (LITE) slips 1%.Okta (OKTA) rises 2% as the stock will replace Kenvue Inc. in the S&P 500 effective Wednesday.Once Upon a Farm (OFRM) falls 12% after the children’s nutritional food company said it will host a business update conference call/webcast at 8:30am NY time to discuss the company’s voluntary recall of its Tractor Wheels soft-baked bars due to potential choking hazard that was issued o…
View source ↗ - News247wallst.com·20d ago·Neutral
Kenvue Is Leaving the S&P 500: Here's What It Means for Investors Kimberly-Clark is absorbing one of the most recognizable brand portfolios in consumer health, and the deal reshapes what investors own across three different indexes at once.
View source ↗ - Newsprnewswire.com·20d ago·Neutral
Kimberly-Clark Completes Acquisition of Kenvue, Creating the Preeminent Global Consumer Health and Wellness Leader Built to Deliver Extraordinary Care to Billions of Consumers Every Day Unites Leading Portfolios, Including 10 Iconic Billion-Dollar Brands, Across Highly Complementary Categories and Geographies Leverages Kimberly-Clark's Powering Care Growth Engine and Proven Operating Model to Drive Value Creation Kimberly-Clark Reiterates Anticipated Run-Rate Synergies of $2.1 Billion, with Valu…
View source ↗ - News (RSS)marketwatch·23d ago·Neutral
This cybersecurity stock will be the next to join the S&P 500 Okta is slated to join the index on Wednesday, replacing Kenvue.
View source ↗ - News (RSS)seekingalpha·23d ago·Negative
Kenvue set to be delisted on Monday before open after Kimberly-Clark deal
View source ↗ - Newszacks.com·23d ago·Positive
Kenvue (KVUE) Surpasses Q3 Earnings Estimates Kenvue (KVUE) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.28 per share a year ago.
View source ↗ - Newswsj.com·23d ago·Neutral
Kenvue Profit, Revenue Rise as Turnaround Efforts Continue Kenvue reported higher profit and revenue as it works to turn around its business ahead of its $40 billion acquisition by consumer-products company Kimberly-Clark.
View source ↗ - Newsbusinesswire.com·23d ago·Neutral
Kenvue Reports Third Quarter 2026 Results SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal third quarter ended September 27, 2026. “We are pleased to have delivered our fourth consecutive quarter of net and organic sales growth, with strong performance in Self Care and Essential Health, along with margin expansion and strong cash generation,” said Kirk Perry, Chief Executive Officer. “Our results reflect continued momentum from disciplined …
View source ↗ - Newszacks.com·24d ago·Neutral
Kenvue's Q3 Earnings on the Horizon: Key Insights for Investors KVUE's Q3 results are likely to benefit from brand-building, product innovation and cost savings, while inflation and cautious consumer spending pressure margins.
View source ↗ - Newsprnewswire.com·26d ago·Neutral
…ffers to exchange (each an "Exchange Offer" and, collectively, the "Exchange Offers") any and all outstanding notes (the "Kenvue Notes") issued by Kenvue Inc. (NYSE: KVUE) ("Kenvue") for up to $7,000,000,000 aggregate principal amount of new notes to be issued by Kimberly-Clark (the "Kimberly-Clark Notes"). Kimberly-Clark hereby extends such expiration date from 5:00 p.m.
View source ↗ - Newsseekingalpha.com·30d ago·Negative
Kimberly-Clark: The Dividend Survives Kenvue, But Expect Token Raises Kimberly-Clark is nearing completion of its $48.7bn acquisition of Kenvue, with key regulatory approvals secured. Current earnings cover the dividend at 69%, but combined FCF only covers it at about 1.07x before $2.5bn in integration costs. Kenvue's Tylenol litigation was revived in July, and they have no reserve for it. A settlement of Zantac-size would be at $2bn and cost $2.50 per share.
View source ↗ - Newsbusinesswire.com·32d ago·Neutral
Kenvue to Announce Third Quarter 2026 Results on October 30, 2026 SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2026 financial results before the market opens on October 30, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure…
View source ↗ - News (RSS)investing·34d ago·Neutral
Kimberly-Clark prices $4.9 billion debt offering for Kenvue deal
View source ↗ - 4chan /biz/biz·34d ago·Neutral
Welcome to Doggo monday, folks. Who else got in on the KVUE/KMB train?
View source ↗ - 4chan /biz/biz·34d ago·Positive
>>62798329 KVUE so you get the merger gainz and make money off bloody holes/wrecked s*******. And picrel, CHWY is getting close to a buy. >F*** I just got my charts back to normal
View source ↗ - News (RSS)zerohedge·34d ago·Neutral
…tors for EUR 39 a share in cash, and Ivanhoe Electric is in advanced talks to sell its US copper assets. Kimberly-Clark could kick off this week's IG issuance as its Kenvue acquisition nears closing, while Citigroup and Wells Fargo launched their first euro bond deals of the year. Elon Musk pledged to give one SpaceX share to "every kid in America" next year, and Hyperscale Data plans to take its AI subsidiary askROI public. Stock futures are rebounding from the Nasdaq's worst week since the tar…
View source ↗ - News (RSS)rte·39d ago·Negative
EU approves Kimberly-Clark's $40 billion Kenvue deal The European Commission has approved Kimberly-Clark's $40 billion acquisition of Tylenol maker Kenvue after the maker of Kleenex tissues and Huggies nappies offered concessions to address EU antitrust concerns.
View source ↗ - News (Finnhub)Reuters·40d ago·Neutral
EU approves Kimberly-Clark's $40 billion Kenvue acquisition - Reuters EU approves Kimberly-Clark's $40 billion Kenvue acquisition Reuters
View source ↗ - Newswsj.com·40d ago·Negative
Kimberly-Clark, Kenvue Win Conditional EU Approval for $40 Billion Tie-Up The European Commission—the EU's executive arm—said that the sale fully addresses officials' earlier concerns that the deal could hinder competition in tampon markets in Czechia, Estonia, and Slovakia.
View source ↗ - News247wallst.com·45d ago·Positive
Market Concentration Is Spooking Wall Street—I'm Buying Kenvue While nervous investors obsess over a handful of tech giants propping up the whole market, one portfolio manager keeps funneling fresh cash into the brands sitting in every American medicine cabinet, and the reasoning might make you rethink your own
View source ↗ - News (RSS)zerohedge·47d ago·Positive
… on prenatal Tylenol and neurodevelopmental disorders. A consumer-safety lead had already called the literature "a safety signal that needs to be evaluated" in 2008. Kenvue, the spun-off maker, still says there is no causal link. Trump moved on the wider schedule in August. An executive order cut routine childhood recommendations to 11 core shots, ended the blanket push for hepatitis B, COVID-19 and influenza in healthy children, and told the Justice Department to challenge states that block rel…
View source ↗ - 4chan /biz/biz·51d ago·Neutral
I'm dry and itchy and Aveeno (ticker: KVUE, formerly JNJ) isn't doing s***
View source ↗ - News247wallst.com·54d ago·Negative
Kimberly-Clark Pays Out Almost Everything It Earns. Can the Dividend Survive the Kenvue Deal? Kimberly-Clark (NASDAQ:KMB | KMB Price Prediction) pays a quarterly dividend of $1.28 per share. That is an annualized forward rate of $5.12 and a yield of 5.16%.
View source ↗ - Newsprnewswire.com·55d ago·Neutral
…SDAQ: KMB) ("Kimberly-Clark") announced today the commencement, in connection with its previously announced pending acquisition ("Acquisition") of Kenvue Inc. (NYSE: KVUE) ("Kenvue"), of an exchange offer (each an "Exchange Offer" and, collectively, the "Exchange Offers") for any and all outstanding notes (the "Kenvue Notes") issued by Kenvue for up to $7,000,000,000 aggregate principal amount of new notes to be issued by Kimberly-Clark (the "Kimberly-Clark Notes") and cash.
View source ↗ - Newsreuters.com·60d ago·Negative
Kimberly-Clark offers remedies in bid for EU approval of Kenvue deal Kimberly-Clark has offered concessions to address EU antitrust concerns about its $40 billion bid for Tylenol maker Kenvue , a filing on the European Commission website showed on Wednesday.
View source ↗ - Newsfool.com·65d ago·Positive
Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue? Johnson & Johnson has raised its dividend for 64 straight years, but faces billions in talc-related litigation liabilities. Kenvue offers a higher yield of 4.71%, but its pending acquisition by Kimberly-Clark creates uncertainty about its dividend outlook.
View source ↗ - News (RSS)seekingalpha·68d ago·Neutral
Kimberly-Clark expected to win EU approval for Kenvue in phase 1 - report
View source ↗ - News (RSS)seekingalpha·69d ago·Neutral
Kimberly-Clark weighs asset sales as EU reviews $40B Kenvue deal
View source ↗ - News (RSS)investing·69d ago·Neutral
Exclusive-Kimberly-Clark readies EU remedies in bid for Kenvue deal, sources say
View source ↗ - 4chan /biz/biz·70d ago·Positive
…hey also own a bunch of stuff that will forever print money like tissue paper, paper towels, toilet paper, pads, bathroom soap they just did a 48.7B deal to acquire Kenvue which makes Tylenol, Motrin, the Neutrogena line, lube, Listerine, Benadryl, sudafed, bandaids, neosporin etc... etc... this company is wayyyy bigger than diapers friendo. its the largest position in my portfolio and I'm not even larping >why are they down they just paid their divvy and they spent 50 billion dollars to buy…
View source ↗ - News247wallst.com·71d ago·Neutral
Kimberly-Clark's 54-Year Dividend Streak Faces Its Biggest Test Yet With $48.7 Billion Kenvue Deal Kimberly-Clark just raised its dividend for the 54th straight year while simultaneously chasing a nearly $50 billion acquisition, and income investors are now weighing whether a deal of that size can coexist with a payout that costs over $1.
View source ↗ - News (RSS)zerohedge·71d ago·Negative
…s Tylenol manufacturers face an ongoing lawsuit in the United States over alleged risks associated with prenatal exposure. Texas Attorney General Ken Paxton has sued Kenvue, which now owns the Tylenol brand after Johnson & Johnson spun off its consumer health business into a new company in 2023. The suit alleged that the company engaged in deceptive advertising by failing to disclose evidence concerning a possible link between prenatal Tylenol exposure and autism. While a judge dismissed most of…
View source ↗ - News (RSS)investing·73d ago·Neutral
Kenvue declares $0.21 quarterly dividend per share
View source ↗ - Newszacks.com·75d ago·Neutral
Kenvue's Brand Strength and Innovation Strategy Support Growth KVUE's trusted brands, innovation and productivity initiatives support growth as it strengthens its consumer health portfolio and global reach.
View source ↗ - Newszacks.com·76d ago·Positive
Should Investors Buy KVUE as Margin Gains Offset Slow Sales Growth? Kenvue's profit margins and cash flow improved in the first half, but modest sales growth, debt and uneven segment trends keep the risk-reward balanced.
View source ↗ - Newszacks.com·76d ago·Negative
Kenvue's Kimberly-Clark Deal Nears Closing With Key Risks Still Ahead KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.
View source ↗ - Newsreuters.com·82d ago·Neutral
Australia clears Kimberly-Clark's acquisition of Kenvue but requires Carefree, Stayfree divestment Australia's competition regulator on Wednesday approved Kimberly-Clark's proposed $40 billion takeover of Kenvue , on condition the company divests Kenvue's Carefree and Stayfree period care brands in the country to address competition concerns.
View source ↗ - News (RSS)investing·86d ago·Neutral
Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
View source ↗ - Newsreuters.com·86d ago·Negative
Kimberly-Clark seeks EU approval for $40 billion Kenvue deal Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.
View source ↗ - News (RSS)seekingalpha·89d ago·Positive
Kenvue Deserves Some Love As Its Purchase By Kimberly-Clark Looks Imminent
View source ↗ - News (RSS)seekingalpha·90d ago·Neutral
Kenvue: Acquisition By Kimberly-Clark Hit An Obstacle - What Now
View source ↗ - News (RSS)investing·94d ago·Neutral
Kimberly-Clark stock trades at a discount as Kenvue deal reshapes the outlook
View source ↗ - 4chan /biz/biz·95d ago·Neutral
>>62609592 It's a pretty profitable strategy to follow s***** women CEOs and see where they land, huge stock price declines usually follow, for example XRX and KSS. Keep an eye on KVUE female leadership has this company well positioned to s*** the bed in the next 12 months.
View source ↗ - Newszacks.com·102d ago·Negative
Kenvue Q2 Deep Dive: Assessing Financial Metrics & Growth Prospects KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Kimberly-Clark: Temporary Headwinds, Strong Innovation And Kenvue Synergies Support A Buy Kimberly-Clark is rated Buy, supported by a strong innovation pipeline, international growth, and upside from the Kenvue acquisition. KMB faces transient headwinds in North America and China, but these are expected to abate, with management forecasting mid- to high-single-digit EPS CAGR from 2026–2028. The Kenvue deal will initially dilute EPS, but synergy realization is tracking ahead of plan, with $1.9B c
View source ↗
Earnings
Tue, Feb 16(in 3 months)
Consensus estimate $0.28 per share
Typical surprise +5.5% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Oct 30$0.29 vs $0.29miss
- Thu, Aug 6$0.31 vs $0.32miss
- Thu, May 7$0.32 vs $0.26beat
- Tue, Feb 17$0.27 vs $0.22beat
- Mon, Nov 3$0.28 vs $0.26beat
- Thu, Aug 7$0.29 vs $0.28beat
Estimates and results for KVUE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KVUE officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 7, 2026 (52d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Aug 11, 2026 (6d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jul 3, 2026 (17d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Apr 8, 2026 (26d later)Sell$1,001 - $15,000
- Kevin Hernhouse · OK01 · disclosed Apr 6, 2026 (20d later)Sell$15,001 - $50,000
- Gilbert Cisneroshouse · CA31 · disclosed Mar 10, 2026 (28d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Feb 13, 2026 (35d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (447d later)Buy$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (104d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2025 (33d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 14, 2025 (38d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Oct 22, 2025 (27d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Sell$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (318d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
